Evidence map›Paper›PMID 40842872›Full record

ArticleFrontiers in medicine2025

Effect of sivelestat sodium on the incidence of ventilator-associated pneumonia in patients with sepsis and ARDS.

Xingcheng Zhang, Zhuangli Li, Xiqun Lei, Huaxue Wang, Nanbing Shan, Yun Sun

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Xingcheng Zhang *The First Department of Critical Care Medicine, The Second Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China.
Zhuangli Li *The First Department of Critical Care Medicine, The Second Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China.
Xiqun LeiDepartment of Critical Care Medicine, Fuyang Second People's Hospital, Fuyang, Anhui, China.
Huaxue WangDepartment of Critical Care Medicine, The First Affiliated Hospital of Bengbu Medical University, Bengbu, Anhui, China.
Nanbing ShanDepartment of Critical Care Medicine, Fuyang Second People's Hospital, Fuyang, Anhui, China.
Yun SunThe First Department of Critical Care Medicine, The Second Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objectives: To evaluate the efficacy of sivelestat sodium in reducing ventilator-associated pneumonia (VAP) in patients with sepsis and acute respiratory distress syndrome (ARDS). Methods: A retrospective analysis was performed on the clinical data of 187 adult patients with sepsis combined with ARDS admitted to the intensive care unit (ICU) of Fuyang Second People's Hospital from 1 January 2022 to 1 December 2024. Among these patients, 60 received sivelestat sodium as part of their treatment, while 127 did not. The treatment efficacy indices were oxygenation index (PaO Results: There were no significant differences in age, sex, comorbidities, use of hormones, use of vasoactive drugs, APACHE II score, or SOFA score between the two groups before treatment. Compared with patients who did not receive sivelestat sodium, those treated with sivelestat sodium had significantly lower incidences of VAP (χ Conclusion: Sivelestat sodium therapy was associated with a reduced incidence of VAP and a shorter ICU stay in patients with ARDS. However, there was no significant benefit on 28 days survival or total hospital stay.

Indexed as

28 days mortalityARDSmechanical ventilationsepsissivelestat sodiumventilator-associated pneumonia

Identifiers

PMID40842872
PMCPMC12364951

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.